




# Hematology, Oncology & Blood & Marrow Transplant for NPs & PAs




## PHARMACOLOGY CONTENT



Select presentations will contain pharmacology content as noted in the program. Identified presentations represent approximately 6.5 hours of pharmacology content.

Saturday, September 8, 2018	
7:00 a.m.	Breakfast & Registration
7:30 a.m.	Welcome and Pre-test Amber B. Koehler, P.A.-C., Darci L. Zblewski, A.P.R.N., C.N.P.
GENERAL SESSION 1	
7:45 a.m.	Keynote Speaker - Wellness Debbie L. Fuehrer, L.P.C.C.
8:30 a.m.	Break
8:35 a.m. 	Hodgkin Lymphoma Robin R. Klebig, A.P.R.N., C.N.P. Objectives: <ul style="list-style-type: none"> <li>• Recognize idiosyncratic symptoms of Hodgkin lymphoma</li> <li>• Understand the importance of adequate biopsy to diagnose Hodgkin lymphoma</li> <li>• Be familiar with how staging impacts treatment decisions in Hodgkin lymphoma</li> <li>• Recognize new treatments and when to use them</li> <li>• Be able to discuss the role of transplant in relapsed Hodgkin lymphoma</li> <li>• Name 2 key survivorship issues to watch for in follow up of Hodgkin lymphoma</li> </ul>
9:05 a.m. 	The Changing Landscape of Chronic Lymphocytic Leukemia: Challenges in the Era of Targeted Therapy Amber B. Koehler, P.A.-C. <ul style="list-style-type: none"> <li>• Objectives: Briefly review chronic lymphocytic leukemia (CLL) and general principles of management</li> <li>• Provide high level overview of FDA-approved oral targeted agents               <ul style="list-style-type: none"> <li>○ Ibrutinib</li> <li>○ Idelalisib</li> <li>○ Venetoclax</li> </ul> </li> <li>• Utilize case studies to review and solidify recognition and management of ibrutinib side effects</li> <li>• Discuss management of patients with CLL progressing on ibrutinib</li> </ul>
9:35 a.m.	Oncologic Emergencies Lucy M. Holmes, A.P.R.N., C.N.P., M.S.N.
10:05 a.m.	Panel Q & A Robin R. Klebig A.P.R.N., C.N.P., Amber B. Koehler, P.A.-C., Lucy M. Holmes, A.P.R.N., C.N.P., M.S.N.

10:25 a.m.	Refreshment Break
<b>PALLIATIVE CARE PANEL</b>	
10:40 a.m.	Difficult Conversations in Cancer Care Joy M. Allen, A.P.R.N., C.N.P., Kelly J. Christensen, P.A.-C., Rachel C. Gentes, A.P.R.N., C.N.P., M.S.N.
12:10 p.m.	Lunch Topical Networking Tables with Expert Faculty <ul style="list-style-type: none"> <li>• Blood and Marrow Transplant - Brenda L. Frye, P.A.-C.</li> <li>• Breast Cancer - Amanda L. Van Beusekom, P.A.-C., M.S.</li> <li>• Oncologic Emergencies and Supportive Cares - Jennie M. Goble, P.A.-C., Lucy M. Holmes, A.P.R.N., C.N.P., M.S.N.</li> <li>• Palliative Care - Joy M. Allen, A.P.R.N., C.N.P., Kelly J. Christensen, P.A.-C., Rachel C. Gentes, A.P.R.N., C.N.P., M.S.N.</li> </ul>
<b>GENERAL SESSION 2</b>	
1:00 p.m. 	Breast Cancer Updates Amanda L. Van Beusekom, P.A.-C., M.S. Objectives: <ul style="list-style-type: none"> <li>• Stage I-III Breast Cancer <ul style="list-style-type: none"> <li>○ Adjuvant HR+/HER2- <ul style="list-style-type: none"> <li>▪ TAILORx</li> <li>▪ SOFT and TEXT Updates from SABCS and ASCO</li> <li>▪ ASTRRA</li> <li>▪ Adjuvant denosumab <ul style="list-style-type: none"> <li>• ABCSG-12 and D-CARE</li> </ul> </li> </ul> </li> <li>○ Adjuvant HER2+ <ul style="list-style-type: none"> <li>▪ PERSPHONE</li> </ul> </li> </ul> </li> <li>• Stage IV highlights</li> </ul>
1:30 p.m. 	Pancreatic Cancer Mindy L. Hartgers, A.P.R.N., C.N.P., M.S. Objectives: <ul style="list-style-type: none"> <li>• Define locally advanced pancreatic cancer</li> <li>• When to refer patient for consideration of surgical resection</li> <li>• Appropriate use of multiple imaging modalities</li> <li>• What systemic treatments are required</li> </ul>
2:00 p.m. 	Pharmacologic Management of CINV and Peripheral Neuropathy Jennie M. Goble, P.A.-C. Objectives: <ul style="list-style-type: none"> <li>• Describe types of CINV</li> <li>• Define risk categories for CINV</li> <li>• Discuss medications for prophylaxis and treatment of CINV</li> <li>• Describe characteristics of CIPN</li> <li>• Define risk categories for CIPN</li> <li>• Discuss treatment strategies for CIPN</li> </ul>





<p>2:30 p.m.</p> 	<p>Panel Q &amp; A  Amanda L. Van Beusekom, P.A.-C., M.S., Mindy L. Hartgers, A.P.R.N., C.N.P., M.S.,  Jennie M. Goble, P.A.-C.  Objectives:</p> <ul style="list-style-type: none"> <li>• Stage I-III Breast Cancer <ul style="list-style-type: none"> <li>○ Adjuvant HR+/HER2- <ul style="list-style-type: none"> <li>▪ TAILORx</li> <li>▪ SOFT and TEXT Updates from SABCS and ASCO</li> <li>▪ ASTRRA</li> <li>▪ Adjuvant denosumab <ul style="list-style-type: none"> <li>• ABCSG-12 and D-CARE</li> </ul> </li> </ul> </li> <li>○ Adjuvant HER2+ <ul style="list-style-type: none"> <li>▪ PERSPHONE</li> </ul> </li> </ul> </li> <li>• Stage IV highlights</li> <li>• Define locally advanced pancreatic cancer</li> <li>• When to refer patient for consideration of surgical resection</li> <li>• Appropriate use of multiple imaging modalities</li> <li>• What systemic treatments are required</li> <li>• Describe types of CINV</li> <li>• Define risk categories for CINV</li> <li>• Discuss medications for prophylaxis and treatment of CINV</li> <li>• Describe characteristics of CIPN</li> <li>• Define risk categories for CIPN</li> <li>• Discuss treatment strategies for CIPN</li> </ul>
<p>2:50 p.m.</p>	<p>Refreshment Break</p>
<p><b>GENERAL SESSION 3</b></p>	
<p>3:00 p.m.</p> 	<p>ALL  Katrina M. Bezak, A.P.R.N., C.N.P.  Objectives:</p> <ul style="list-style-type: none"> <li>• Understand the backbone therapy for current treatment of ALL</li> <li>• Distinguish the different indications and adverse effects for the recent therapies of ALL</li> <li>• Identify the potential complications of future ALL treatment in regards to CAR-T therapy</li> </ul>
<p>3:30 p.m.</p>	<p>Complications of Blood and Marrow Transplant  Brenda L Frye, P.A.-C.</p>
<p>4:00 p.m.</p> 	<p>Updates in GVHD Management  Kimberly J. Langer, A.P.R.N., C.N.P. D.N.P.  Objectives:</p> <ul style="list-style-type: none"> <li>• Describe current prognosis and management of acute GVHD</li> <li>• Describe the role of new biomarkers in prognostication and management</li> <li>• Epidemiology, risks &amp; clinical presentation of chronic GVHD (cGVHD)</li> <li>• Treatment Principles of cGVHD, treatment of cGVHD targeted organs</li> <li>• Future Prospects</li> </ul>



4:30 p.m.	Panel Q & A Katrina M. Bezak, A.P.R.N., C.N.P., Brenda L. Frye, P.A.-C., Kimberly J. Langer, A.P.R.N., C.N.P.
4:50 p.m.	Adjourn
5:00 p.m.	Wine and Cheese Networking Reception Hage Atrium



**Sunday, September 9<sup>th</sup>, 2018**

7:00 a.m.	Breakfast
-----------	-----------

**GENERAL SESSION 4**

7:30 a.m. 	Gastroesophageal Cancer Rachel A. Eiring, P.A.-C. Objectives: <ul style="list-style-type: none"> <li>• Overview</li> <li>• Curative Intent treatment <ul style="list-style-type: none"> <li>○ Esophageal/ GE junction adenocarcinoma <ul style="list-style-type: none"> <li>▪ Review of NCCN guidelines and evidence</li> </ul> </li> <li>○ Gastric adenocarcinoma <ul style="list-style-type: none"> <li>▪ Surgery, perioperative chemotherapy, and chemoradiation</li> </ul> </li> </ul> </li> </ul>
8:00 a.m. 	Amyloidosis Miriam A. Hobbs, A.P.R.N., C.N.P., D.N.P. Objectives: <ul style="list-style-type: none"> <li>• Recognize the presentation of amyloidosis</li> <li>• Understand diagnostic workup</li> <li>• Review treatment approaches</li> <li>• Provide clinical pearls</li> </ul>
8:30 a.m. 	Management of VTE in Cancer Patients Jessica L. Shelly, A.P.R.N., C.N.P. Objectives: <ul style="list-style-type: none"> <li>• Discuss factors that influence the decision to anticoagulate</li> <li>• Drugs of choice for treatment of VTE in cancer patients</li> <li>• Discuss factors that determine length of anticoagulation</li> </ul>
9:00 a.m. 	Panel Q & A Rachel A. Eiring, P.A.-C., Miriam A. Hobbs, A.P.R.N., C.N.P., D.N.P., Jessica L. Shelly, A.P.R.N., C.N.P. Objectives: <ul style="list-style-type: none"> <li>• Overview</li> <li>• Curative Intent treatment <ul style="list-style-type: none"> <li>○ Esophageal/ GE junction adenocarcinoma <ul style="list-style-type: none"> <li>▪ Review of NCCN guidelines and evidence</li> </ul> </li> <li>○ Gastric adenocarcinoma <ul style="list-style-type: none"> <li>▪ Surgery, perioperative chemotherapy, and chemoradiation</li> </ul> </li> </ul> </li> <li>• Recognize the presentation of amyloidosis</li> <li>• Understand diagnostic workup</li> </ul>

	<ul style="list-style-type: none"> <li>• Review treatment approaches</li> <li>• Provide clinical pearls</li> <li>• Discuss factors that influence the decision to anticoagulate</li> <li>• Drugs of choice for treatment of VTE in cancer patients</li> <li>• Discuss factors that determine length of anticoagulation</li> </ul>
9:20 a.m.	Refreshment Break
<b>GENERAL SESSION 5</b>	
9:30 a.m.	Radiation Oncology: Education for the Nurse Practitioner and Physician Assistant Sydney L. Schone, A.P.R.N., C.N.P., D.N.P.
10:00 a.m. 	<b>HPV Associated Oropharynx Cancer</b> Casey A. Fazer, P.A.-C. Objectives: <ul style="list-style-type: none"> <li>• Understand the epidemiology and risk factors for HPV-associated oropharynx cancer (HPV-OPC)</li> <li>• Review the clinical features of HPV-associated oropharynx cancer</li> <li>• Review the new AJCC 8th Edition Staging guidelines for HPV-associated oropharynx cancer</li> <li>• Review current strategies for treatment and new de-escalating treatment for patients with HPV-associated oropharynx cancer</li> <li>• Review treatment side-effects and management</li> <li>• Understand the current state of HPV vaccination in the United States</li> </ul>
10:30 a.m.	Brain Tumors Sani H. Kizilbash, M.D., M.P.H.
11:00 a.m.	Panel Q & A Sydney L. Schone, A.P.R.N., C.N.P., D.N.P., Casey A. Fazer, P.A.-C., Sani H. Kizilbash, M.D., M.P.H.,
11:10 a.m. 11:30 a.m.	Lunch Yoga with Miriam A. Hobbs
<b>RADIOLOGY PANEL</b>	
11:50 a.m.	Radiology Panel: Reading Chest X-Rays, CTs, and PET scans Geoffrey B. Johnson, M.D., Ph.D.
<b>GENERAL SESSION 6</b>	
1:00 p.m. 	<b>Melanoma</b> Lisa A. Kottschade, A.P.R.N., C.N.P. Objectives: <ul style="list-style-type: none"> <li>• List the changes in staging criteria with the release of AJCC v. 8.0</li> <li>• Discuss the updates of the following in the management of stage III disease: <ul style="list-style-type: none"> <li>○ Surgery</li> <li>○ Immunotherapy</li> <li>○ Targeted therapy</li> </ul> </li> <li>• Understand the advances in systemic therapy for metastatic disease</li> </ul>

<p>1:30 p.m.</p> 	<p>Fertility Preservation in Patients with Hematologic and Oncologic Malignancies          Jessica L. Bleess, P.A.-C.          Objectives:</p> <ul style="list-style-type: none"> <li>• Review the current state of fertility preservation technologies for males and females</li> <li>• Provide an algorithm of fertility preservation treatment options</li> <li>• Explore the availability of fertility preservation resources at Mayo Clinic</li> </ul>
<p>2:00 p.m.</p> 	<p>Panel Q&amp;A          Lisa A. Kottschade, A.P.R.N., C.N.P., Jessica Bleess, P.A.-C.          Objectives:</p> <ul style="list-style-type: none"> <li>• List the changes in staging criteria with the release of AJCC v. 8.0</li> <li>• Discuss the updates of the following in the management of stage III disease:             <ul style="list-style-type: none"> <li>○ Surgery</li> <li>○ Immunotherapy</li> <li>○ Targeted therapy</li> </ul> </li> <li>• Understand the advances in systemic therapy for metastatic disease</li> <li>• Review the current state of fertility preservation technologies for males and females</li> <li>• Provide an algorithm of fertility preservation treatment options</li> <li>• Explore the availability of fertility preservation resources at Mayo Clinic</li> </ul>
<p>2:15 p.m.</p>	<p>Course Wrap Up &amp; Post –test          Amber B. Koehler, P.A.-C., Darci L. Zblewski, A.P.R.N., C.N.P.</p>
<p>2:30 p.m.</p>	<p>Course Adjourns</p>